• Je něco špatně v tomto záznamu ?

The role of carboplatin in combination with paclitaxel in patients with castration-resistant prostate cancer

N. Rusarova, D. Vitaskova, H. Kalabova, A. Ondruskova, D. Purova, B. Melichar, H. Studentova

. 2022 ; 18 (38) : 4183-4192. [pub] 20221215

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004920

Background: The aim of the present study was to examine the efficacy of carboplatin in combination with paclitaxel in patients with metastatic castration-resistant prostate cancer pretreated with multiple regimens including docetaxel and androgen receptor-targeted agents. Methods: Clinical data from patients treated with carboplatin plus paclitaxel were collected retrospectively from a single institution. Results: 43 patients with metastatic castration-resistant prostate cancer were identified. Median number of cycles was ten (range: 1 to 23), prostate-specific antigen response was observed in 18 (42%) patients, median progression-free survival was 115 days and median overall survival was 8.1 months. Conclusion: Combination chemotherapy using taxane with carboplatin is an effective and well-tolerated therapy in heavily pretreated patients with metastatic castration-resistant prostate cancer.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004920
003      
CZ-PrNML
005      
20230425171809.0
007      
ta
008      
230418s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.2217/fon-2022-0914 $2 doi
035    __
$a (PubMed)36519589
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Rusarova, Nikol $u Department of Oncology, Palacky University, Faculty of Medicine & Dentistry & University Hospital Olomouc, Olomouc, 77900, Czech Republic
245    14
$a The role of carboplatin in combination with paclitaxel in patients with castration-resistant prostate cancer / $c N. Rusarova, D. Vitaskova, H. Kalabova, A. Ondruskova, D. Purova, B. Melichar, H. Studentova
520    9_
$a Background: The aim of the present study was to examine the efficacy of carboplatin in combination with paclitaxel in patients with metastatic castration-resistant prostate cancer pretreated with multiple regimens including docetaxel and androgen receptor-targeted agents. Methods: Clinical data from patients treated with carboplatin plus paclitaxel were collected retrospectively from a single institution. Results: 43 patients with metastatic castration-resistant prostate cancer were identified. Median number of cycles was ten (range: 1 to 23), prostate-specific antigen response was observed in 18 (42%) patients, median progression-free survival was 115 days and median overall survival was 8.1 months. Conclusion: Combination chemotherapy using taxane with carboplatin is an effective and well-tolerated therapy in heavily pretreated patients with metastatic castration-resistant prostate cancer.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    _2
$a karboplatina $x terapeutické užití $7 D016190
650    12
$a paclitaxel $x terapeutické užití $7 D017239
650    12
$a nádory prostaty rezistentní na kastraci $x patologie $7 D064129
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a docetaxel $x terapeutické užití $7 D000077143
650    _2
$a prostatický specifický antigen $x terapeutické užití $7 D017430
650    _2
$a výsledek terapie $7 D016896
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $7 D000971
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vitaskova, Denisa $u Department of Oncology, Palacky University, Faculty of Medicine & Dentistry & University Hospital Olomouc, Olomouc, 77900, Czech Republic
700    1_
$a Kalabova, Hana $u Department of Oncology, Palacky University, Faculty of Medicine & Dentistry & University Hospital Olomouc, Olomouc, 77900, Czech Republic
700    1_
$a Ondruskova, Andrea $u Department of Oncology, Palacky University, Faculty of Medicine & Dentistry & University Hospital Olomouc, Olomouc, 77900, Czech Republic
700    1_
$a Purova, Dana $u Olomouc University Social Health Institute, Palacky University Olomouc, Olomouc, 77900, Czech Republic
700    1_
$a Melichar, Bohuslav $u Department of Oncology, Palacky University, Faculty of Medicine & Dentistry & University Hospital Olomouc, Olomouc, 77900, Czech Republic
700    1_
$a Studentova, Hana $u Department of Oncology, Palacky University, Faculty of Medicine & Dentistry & University Hospital Olomouc, Olomouc, 77900, Czech Republic $1 https://orcid.org/0000000321059258
773    0_
$w MED00008687 $t Future oncology (London, England) $x 1744-8301 $g Roč. 18, č. 38 (2022), s. 4183-4192
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36519589 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425171805 $b ABA008
999    __
$a ok $b bmc $g 1925172 $s 1191129
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 18 $c 38 $d 4183-4192 $e 20221215 $i 1744-8301 $m Future oncology $n Future Oncol $x MED00008687
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace